|
Vectura' $45m asthma drug haul just the start
Business Weekly Cambridge UK pharma company Vectura is drawing down the first development milestone payment – $3 million – in September from a US customer involved in commercialising its VR315 asthma/COPD programme. Vectura today reiterated that is eligible to … Vectura Group says Financial Performance In Line With Board's Expectations |
View full post on asthma – Google News